Podium to Practice: ASH® 2025 – LYMPHOMA: Real-World Pola-R-CHP Outcomes in Frail Older Adults with DLBCL

Explore more from your favourite experts – click their name to access their entire library of content.

Studies / Trials Discussed

ID 784 – Real-world outcomes of frontline polatuzumab-rchp and impact of frailty in older adults with diffuse large B-cell lymphoma

This program has been made possible through unrestricted support from Eli Lilly and Merck.

Studies/trials discussed:

ID 784 – Real-world outcomes of frontline polatuzumab-rchp and impact of frailty in older adults with diffuse large B-cell lymphoma